

ASX ANNOUNCEMENT

5 January 2022

ANTERIS STRENGTHENS ITS IP PORTFOLIO WITH NEW PATENT APPLICATION FOR ADAPT®

Brisbane, Australia and Minneapolis, USA, Anteris Technologies Ltd (ASX: AVR) (**Anteris** or the **Company**) reports that it has filed a provisional application for a new patent pertaining to ADAPT®.

The new patent adds to the current patent family as well as sets new patent protections into the future for the ADAPT® process. Internally dubbed “ADAPT® 2.0” the new patent specifically applies to particular aspects of the sterilization process allowing the safe transfer of product to manufacturer of valves.

“This new process opens up the potential for additional manufacturing sites for the Company globally as volumes increase, as well as allowing the Company to ramp up valve production (due to the extended shelf life before the manufacturing step).

ADAPT® 2.0 will allow expanded manufacturing capacity of DurAVR™ at additional sites by starting the process in our Australian facility and completing valve manufacture at our US facility, saving significant time and money in the process. This is important as we enter the expanded clinical trial phase and for commercialization,” CEO Wayne Paterson said.

ENDS

About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd is a structural heart company that delivers clinically superior and durable solutions through better science and better design.

Its focus is developing next-generation technologies that help healthcare professionals reproduce consistent life-changing outcomes for patients.

Anteris’ DurAVR™ 3D single-piece aortic heart valve replacement addresses the needs of tomorrow’s younger and more active aortic stenosis patients by delivering superior performance and durability through innovations designed to last the remainder of a patient’s lifetime.

The proven benefits of its patented ADAPT® tissue technology, paired with the unique design of our DurAVR™ 3D single-piece aortic heart valve, have the potential to deliver a game-changing treatment to aortic stenosis patients worldwide and provide a much-needed solution to the challenges facing doctors today.

Authorisation and Additional information

This announcement was authorised by the Board of Directors.

Anteris Technologies Ltd Registered Office:

Toowong Tower, Suite 302, Level 3, 9 Sherwood Rd, Toowong, Queensland, 4066

Customer Service

T +61 1300 550 310 | F +61 1300 972 437 | E info@anteristech.com | W anteristech.com

Brisbane • Minneapolis • Geneva • Malaga



For more information:

Hannah Howlett

WE Communications

E: WE-AUAnterisTech@we-worldwide.com

P: +61 4 5064 8064

www.anteristech.com

Twitter: @AnterisTech

Facebook: www.facebook.com/AnterisTech